Refine
Estimated Years
6,279 results foundRefine Search
A&8.S.6 - 06D PFOS Repeat Dose - 000066 Pathology Associates International A Company of Science Applications International Corporation An Employee Owned Company Dr.
Document imageDocument imageDocument imageDocument image
refid# Ed1n3boLdk69JK7E843wj212g35 pages
Ad a.a.6 - 0768 BIODEGRADATION (BOD/COD) TEST SUBSTANCE_______________________________________________ Identity: Mixture containing perfluorooctanesulfonate which may also be referred to as PFOS, FC-95, or as a component of FC-203FC. (1Octanesulfonic acid) (CAS # 2795-39-3).
Document imageDocument imageDocument imageDocument image
refid# 8V1z3jvYjxLRZq7dejyLYL3ey6 pages
A h * 2.6 - 0 7 S Z ACUTE TOXICITY TO FISH (RAINBOW TROUT) TEST SUBSTANCE_______________________________________________ Identity: A mixture containing perfluorooctanesulfonate, which may also be referred to as PFOS, FC-95, or as a component of FC-206 or L3243. (1-Octanesulfonic acid) (CAS # 2795-39-3).
Document imageDocument imageDocument image
refid# 3JM15pK4w9w3jE04BLen8znkJ3 pages
M &Z6 - ACUTE TOXICITY TO FISH (FATHEAD MINNOW) TEST SUBSTANCE___________________________________________ Identity: A mixture containing perfluorcoctanesulfonate, which may also be referred to as PFOS, FC-95, or as a component of FC-600. (1-Octanesulfonic acid, 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8heptadecafluoro-, potassium salt, CAS # 2795-39-3) Remarks: The 3M production lot number was 628.
Document imageDocument imageDocument imageDocument image
refid# gDbkqjb1G0XJo546aEqDNrRwe4 pages
4R & S- 09th7 mo Oh < Telomer Research Program Update and Status Report Presented to U.S.
Document imageDocument imageDocument imageDocument image
refid# g2zxGw04wGD0VJ2ee6VDX54mL153 pages
gGH& - 0 2 0 0 - $ 1 5 J R zz6 -0 % lys -y Laboratory Report, Analysis of FCs in Samples of Children's Sera, May 21, 1999 The data submitted on perfluorooctanesulfonate contains analytic data when certain general conditions have been met.
Document imageDocument imageDocument imageDocument image
refid# v1oMdLBnb1L3X5L0vgVxM8d2Y66 pages
NO RTHERN KEN TU CKY OFFICE SU IT E 340 1717 D IXIE H IG H W A Y CO VINGTO N, K E N T U C K Y 41011-4704 606-331-2938 513-381-2838 FAX. 513-381-6613 Robert a .
Document imageDocument imageDocument image
refid# 4JnbNovJ2G3edBdr0nG547koR3 pages
NORTHERN KENTUCKY QFF,CE SUITE HO 'TIT OIXIE HIGHWAY COVINGTON KENTUCKY 4 '0 " -*T0A 5!
Document imageDocument imageDocument imageDocument image
refid# XOGxwEXdkXge7wYBqmZkREgvy15 pages
M S Q G - ta. g*?
Document imageDocument imageDocument imageDocument image
refid# JJoj8kygGjXrE0OBygNnpKv1B8 pages
ft HcKG -- I 6 6 LABORATORY-SCALE THERMAL DEGRADATION OF PERFLUOROOCTANYL SULFONATE AND RELATED SUBSTANCES TEST SUBSTANCE________________________________________ Identity: Perfluorooctanesulfonate; may also be referred to as PFOS or C8F i7S0 3'K+. (1-Octanesulfonic acid, 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-, potassium salt, CAS # 2795-39-3).
Document imageDocument imageDocument imageDocument image
refid# 375zwg6qyOV91ovEBd2mBqq7y13 pages
r ..... ..--
Document imageDocument imageDocument imageDocument image
refid# ka9vr37m07K2qqwVD0xVX6ewq11 pages
M , 6 _ s t a t u s 'r e v i e w FLUOROCHEMICALS IN BLOOD 5/22/79, PGG On May 30, 1978, 3M informed Du Pont of findings of organic fluorocarbons in blood of employees exposed* to long-chain perfluoro surface-active materials.
Document imageDocument imageDocument imageDocument image
refid# 2J6g07652Yx8wrLypwD0a3R2516 pages
r Afua.6- <*+69 o 0 IW V.
Document imageDocument image
refid# 3Nro1rNM0D6NmdQzZqEd978zn2 pages
_ 14fe D u P on t-13309 Perfluorooctanoic Acid: Lactational and Placental Transport Pharmacokinetic Study in Rats Work Request Number 14787 Service Code 1569 Protocol Haskell Animal W elfare Committee Number: <> -1- RECEIVED 0PPTNC1C 2803SEP -* AH 8*1* 5 Perfluorooctanoic Acid: Lactational and Placental Transport Phannacokinetic Study in Rats D u P on t-13309 TABLE OF CONTENTS Page INTRODUCTION...............................................................................................................................3 OBJECTIVE........................................................................................................................................ 3 SPONSOR AND TEST FACILITY............. ....................................................................................3 REGULATORY COMPLIANCE.....................................................................................................3 STUDY DESIGN................................................................................................................................4 A.
Document imageDocument imageDocument imageDocument image
refid# Qk9Qra1GL8Xqk34DJ11Edxxy713 pages
Date: Sat, 30 Aug 2003 07:17:34 -0500 >To: Charlie Auer, steve.johnson@epamail.epa.gov >From: rich purdy <rpurdy@pressenter.com> >Subject: postponing of risk assessment.
Document imageDocument image
refid# m3Ey51NZjVmOReKy2M30jyq42 pages